Results 61 to 70 of about 23,157 (220)

Real-world efficacy and safety of switching to bictegravir/emtricitabine/tenofovir alafenamide in older people living with HIV

Medicine, 2021
Approximately 50% of people living with HIV (PLWH) in the United States are ≥50 years old. Clinical trials of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) demonstrated potent efficacy and favorable safety in older PLWH; however, real-world ...
Charlotte-Paige Rolle, V. Nguyen, Kiran Patel, D. Cruz, E. Dejesus, F. Hinestrosa   +5 more
semanticscholar   +1 more source

Material deprivation and its correlates in treatment‐naïve migrants with HIV with rapid access to B/F/TAF at no cost: A sub‐study of the ASAP cohort

HIV Medicine, EarlyView.
Abstract Objectives Material deprivation (MD), the inability to afford essentials, is linked with poorer HIV clinical outcomes. In Canada, migrants living with HIV are a growing group, yet little is known about their experience of MD, especially early in treatment. This study examined the prevalence, nature, sociodemographic and clinical correlates and
Moustafa Laymouna, Kim Engler, David Lessard, Melchior Belin, Serge Vicente, Dominic Chu, Sean Yaphe, Joseph Cox, Nadine Kronfli, Jean‐Pierre Routy, Joel Ishak, Alexandra Hamel, Marina Klein, Alexandra de Pokomandy, Cecilia T. Costiniuk, Bertrand Lebouché   +15 more
wiley   +1 more source

Why Are Patients Switching from Tenofovir Disoproxil Fumarate/Emtricitabine (Truvada) to Tenofovir Alafenamide/Emtricitabine (Descovy) for Pre-Exposure Prophylaxis?

AIDS Patients Care and STDs, 2021
Safety differences between tenofovir alafenamide/emtricitabine (TAF) and tenofovir disoproxil fumarate/emtricitabine (TDF/FTC)-formulated pre-exposure prophylaxis (PrEP) appear to have little clinical significance for most PrEP users.
Alexa B. D’Angelo, D. Westmoreland, Pedro B. Carneiro, Jeremiah Johnson, C. Grov   +4 more
semanticscholar   +1 more source

Factors driving decisions in the use of HIV pre-exposure prophylaxis: a real-world study in the United States

HIV Research & Clinical Practice
Background: Uptake of pre-exposure prophylaxis (PrEP) in the United States (US) remains below target, despite reported high efficacy in prevention of HIV infection and being considered as a strategy for ending new HIV transmissions.
Yohance Whiteside, Abigail McMillan, Fritha Hennessy, Phoebe Salmon, Tim Holbrook, Bekana K. Tadese   +5 more
doaj   +1 more source

Parasomnias and sleep‐related movement disorders induced by drugs in the adult population: a review about iatrogenic medication effects

Journal of Sleep Research, Volume 34, Issue 2, April 2025.
Summary Parasomnias and sleep‐related movement disorders (SRMD) are major causes of sleep disorders and may be drug induced. The objective of this study was to conduct a systematic review of the literature to examine the association between drug use and the occurrence of parasomnias and SRMD.
Sylvain Dumont, Vanessa Bloch, Agnès Lillo‐Lelouet, Christine Le Beller, Pierre A. Geoffroy, Marc Veyrier   +5 more
wiley   +1 more source

Validation of an UHPLC–MS/MS Assay for the Quantification of Isoniazid and Four Major Metabolites in Human Plasma

Biomedical Chromatography, Volume 40, Issue 9, September 2026.
ABSTRACT Isoniazid (INH) is a key component of tuberculosis treatment regimens but is also associated with hepatotoxicity. This toxicity is mediated in part by its metabolites, but some degrade rapidly in plasma. A rapid freeze/thaw process with a methanol protein precipitation extraction was developed to slow the rapid degradation of acetylisoniazid ...
David Nerguizian, Brandon Klein, Farah Abdelmawla, Joe Gomez, Peter L. Anderson, Lane Bushman, Kristina M. Brooks   +6 more
wiley   +1 more source

Pharmacokinetic interaction of riociguat and antiretroviral combination regimens in HIV-1-infected adults

Pulmonary Circulation, 2019
Riociguat, a first-in-class soluble guanylate cyclase stimulator, is approved for the treatment of pulmonary arterial hypertension (PAH), a serious potential complication of human immunodeficiency virus (HIV) infection. This open-label study investigated
Edwin DeJesus, Soundos Saleh, Sue Cheng, Dorina van der Mey, Corina Becker, Reiner Frey, Sigrun Unger, Wolfgang Mueck   +7 more
doaj   +1 more source

Validation of a Point‐Of‐Care Ultrasound for Hepatitis Among Front‐Line Healthcare Workers Managing Chronic Hepatitis B Virus Infection in Zambia

Journal of Viral Hepatitis, Volume 33, Issue 9, September 2026.
ABSTRACT To close gaps in implementing care of people with hepatitis B virus (HBV) infection in resource‐limited settings, we evaluated the accuracy of a novel liver point‐of‐care ultrasound (POCUS) protocol for hepatitis (PUSH) among front‐line non‐radiology healthcare workers in Zambia. At University Teaching Hospital in Lusaka, Zambia, from March to
Costanza Bertoni, Annie Kanunga, Edford Sinkala, Enock Syabbalo, Helen Chitundu, Alick Chikwezi, Carolyn Chibundi, Guy K. Muula, Samuel Bosomprah, Nicolò Capra, Riccardo Lolatto, Giulia Morsica, Antonella Castagna, Claudia Wallrauch, Tom Heller, Michael J. Vinikoor   +15 more
wiley   +1 more source

Impact of treatment adherence on efficacy of dolutegravir plus lamivudine and dolutegravir plus tenofovir disoproxil fumarate/emtricitabine: pooled analysis of the GEMINI-1 and GEMINI-2 clinical studies

HIV Research & Clinical Practice, 2021
Background: GEMINI-1 and GEMINI-2 (ClinicalTrials.gov, NCT02831673 and NCT02831764, respectively) are double-blind, multicenter, phase III studies that demonstrated the non-inferiority of once-daily dolutegravir + lamivudine to dolutegravir + tenofovir ...
Mounir Ait-Khaled, Juan Sierra Madero, Vicente Estrada, Roberto Gulminetti, Debbie Hagins, Hung-Chin Tsai, Choy Man, Jörg Sievers, Richard Grove, Andrew Zolopa, Brian Wynne, Jean van Wyk   +11 more
doaj   +1 more source

PrEP at the site of action in cisgender and transgender women: A pharmacology study of blood and rectal CD4+ lymphocytes

British Journal of Clinical Pharmacology, Volume 92, Issue 8, Page 2949-2959, August 2026.
Background Female sex hormones used in feminizing hormone therapy (FHT) may influence activation and persistence of HIV pre‐exposure prophylaxis (PrEP) medications. The clinical relevance of this interaction remains unclear, particularly for transgender and cisgender women (TGW and CGW).
Elizabeth Hastie, Megha Srivasta, Edward R. Cachay, Leah Burke, Sara Gianella, Stephen Rawlings, Frank Z. Stanczyk, Craig Sykes, Angela D. M. Kashuba, Jill Blumenthal, Mackenzie L. Cottrell   +10 more
wiley   +1 more source